Meeting
2018 Gastrointestinal Cancers Symposium
A comparison of doublet versus triplet chemotherapy regimens for esophagogastric adenocarcinoma (EGC): Is more always better?
Authors
Tiago Felismino
A.C. Camargo Cancer Center, São Paulo, Brazil
Tiago Felismino , Ana Caroline Alves , Audrey Oliveira , Wilson Luiz da Costa Jr., Felipe José Fernandez Coimbra , Victor Hugo Fonseca Jesus , Marcos Pedro Guedes Camandaroba , Celso Lopes Mello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 124)
DOI
10.1200/JCO.2018.36.4_suppl.124
Abstract #
124
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
First Author: Thomas Adam Abrams
Poster
2021 Gastrointestinal Cancers Symposium
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable esophagogastric junction adenocarcinoma: A retrospective study.
First Author: Toshiharu Hirose
Poster
2019 ASCO Annual Meeting
Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience.
First Author: Megan Greally
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.
First Author: James Tankel